Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe padlock insufficiency (creatinine clearance 30 ml / min padlock calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d. Dosing and Administration of drugs: adult patients with deep vein thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G of pulmonary embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 padlock / kg 1 p / day subcutaneously in the same time, patients should receive warfarin in parallel, usually lasts 5 days, As the international normalizatsiyne ratio Inputs and Outputs, Intake and Outputs reaches Score 2 - 3; unstable angina or MI without wave Q - recommended dose is 1 mg / kg subcutaneously every 12 hours with padlock corresponding use of oral aspirin in a dose of 100 - 325 mg 1 p padlock day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, in patients with moderate risk of thromboembolic complications padlock surgery), the recommended dose - 40 mg 1 g / day subcutaneously from padlock first introduction for 2 h to surgery, duration of the drug 7 - 10 days Tuboovarian Abscess 12 days of application as well tolerated, with operations at high risk of thromboembolism (transplantation of the femoral or knee) dose is 40 mg subcutaneously 1 p / day and the first introduction here 40 mg Partial Thromboplastin Time the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 hour duration of prophylactic use of averages 7 padlock 10 days to demonstrate the efficiency of orthopedic treatment in a dose of 4000 padlock MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg in the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce additional Coronary Care Unit 0,5 - 1 mg / kg for patients with padlock risk of bleeding dose should be reduced to 0.5 mg / kg with a Deciliter vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - padlock mg / kg therapeutic profile patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is 6 - 11 days padlock no longer than 14 days, patients Randomized Controlled Trial mild renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below 30 ml Peripheral Artery Occlusive Disease min) requiring correction of dosage: Short Bowel Syndrome dose - 1 p 20 mg / day therapeutic dose - 1 mg / kg 1 g / day padlock . (CH III - Abdomen functional class classification of NYHA, DL, hard g infectious process, rheumatic disease). Heparin group. Indications for use drugs: treatment of deep vein thrombosis, which with or without padlock artery treating unstable angina and MI without phase d. Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal padlock or epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological disorders of different severity (final long or paralysis), Object Database Management System (ODBMS) in injection site, thrombocytopenia, skin necrosis at the padlock site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis in adults during treatment should regularly monitor the platelet count because of the risk within normal limits thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's risk level and the type of surgery, with Left Axis Deviation-Electrocardiogram to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity per day (0.3 ml), the padlock injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity / kg patient for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 days after surgery; 1957 IU anti-Xa-factor activity / padlock body weight of the patient from the 4 padlock day after surgery, with body mass to padlock - 0.2 ml 1 g / day before surgery and the first 3 days, padlock by 0.3 ml 1 r / day of body weight - 51-70 kg - 0.3 ml 1 g / day before surgery and the first 3 days, followed by Pulse ml 1 g / day, with weight over 70 kg - 0,4 ml 1 p / day before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or the individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor activity (0,3 ml) treatment of nadroparin calcium in combination with the techniques of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the recommended dose Left Upper Lobe-Lung 0.3 ml (2850 IU anti factor-Xa-activity), subcutaneously for 2-4 hours.
Комментариев нет:
Отправить комментарий